Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis

International Journal of Molecular Sciences

Alberto D’Angelo¹  Giandomenico Roviello²  Enrico Mini²  Stefania Nobili²  SilviaPaola Corona³  Pietro Rosellini⁴ 

[1] Department of Biology and Biochemistry, University of Bath, Bath BA2 7AY, UK;Department of Health Sciences, University of Florence, 50139 Florence, Italy;Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital-Strada di Fiume 447, 34149 Trieste, Italy;Unit of Medical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Viale Bracci-Policlinico “Le Scotte”, 53100 Siena, Italy;

关键词: nivolumab;    pd-1;    pd-l1;    immunotherapy;    gastric cancer;   

DOI  :  10.3390/ijms21020448

来源: DOAJ

【 摘 要 】

Immunotherapy has recently changed the treatment of several cancers. We performed a literature-based meta-analysis of randomised controlled trials to assess the efficacy of the novel immune checkpoint inhibitors (ICIs) in metastatic gastric cancer. The main outcome was overall survival. Based on age (cut-off agreed at 65 years), tumour location (gastric vs. gastro-oesophageal junction), programmed death-ligand 1 (PD-L1) status, sex and Eastern Cooperative Oncology Group (ECOG) status (1 vs. 0), we scheduled a subgroup analysis for the overall survival. Three studies were included in the analysis for a total of 1456 cases (811 cases were in the experimental group and 645 cases in the control group). The pooled analysis showed improved overall survival in the experimental arm in the absence of statistical significance (hazard ratio (HR) = 0.87, 95% CI: 0.64−1.18; p = 0.37). The subgroup of patients with PD-L1-positive tumours (HR = 0.82 vs. 1.04) and gastro-oesophageal junction cancer (HR = 0.82 vs. 1.04) showed a statistically significant advantage of overall survival. This study supports the efficacy of immune checkpoint inhibitors in the subgroup of patients with metastatic gastric cancer with PD-L1-positive and gastro-oesophageal junction tumour location. Future studies are needed with the aim of identifying reliable predictive biomarkers of ICI efficacy.

【 授权许可】

Unknown